# Prognostic Role of Circulating Tumor DNA in Resectable Pancreatic Cancer

> **NCT04246203** · — · ACTIVE_NOT_RECRUITING · sponsor: **Ludwig-Maximilians - University of Munich** · enrollment: 200 (estimated)

## Conditions studied

- Pancreas Cancer

## Interventions

- **OTHER:** Liquid Biopsy

## Key facts

- **NCT ID:** NCT04246203
- **Lead sponsor:** Ludwig-Maximilians - University of Munich
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-12-12
- **Primary completion:** 2025-12-01
- **Final completion:** 2026-12-01
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2025-03-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04246203

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04246203, "Prognostic Role of Circulating Tumor DNA in Resectable Pancreatic Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04246203. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*